Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | CPN1 | P15169 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739703 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| SCHEMBL20215890 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| SCHEMBL738380 | 0.86 | — | — | |
| SCHEMBL12651661 | 0.86 | — | — | |
| SCHEMBL3631001 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL31321244 | 0.84 | HTR2C (0.33) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL31321233 | 0.84 | HTR2C (0.33) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL18036209 | 0.84 | HTR2C (0.33) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL18036210 | 0.84 | HTR2C (0.33) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| SCHEMBL15546783 | 0.83 | SLC6A1 (0.35) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | CHRNB2 3019/4885CHRNA4 1288/4885CHRM2 1896/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | CHRNB2 3177/4885CHRNA4 1164/4885CHRM2 2230/4885 |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | NFKBIA, TBKBP1, TBK1 | CHRNB2 3111/4885CHRNA4 3885/4885CHRM2 4598/4885 |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | TGFBR2, SMAD2, ACVR2A | CHRNB2 1798/4885CHRNA4 3726/4885CHRM2 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.